If a patient has elevated serum creatinine indicating impaired renal function, should the cefixime dose be adjusted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefixime Dosing in Elevated Creatinine

Yes, elevated creatinine requires dose adjustment for cefixime when creatinine clearance falls below 60 mL/min, but the drug can still be safely administered with appropriate modifications. 1

Dose Adjustment Algorithm

For patients with renal impairment, adjust cefixime dosing based on creatinine clearance (CrCl) as follows:

Adults with Renal Impairment 1

  • CrCl ≥60 mL/min: No adjustment needed—use standard 400 mg daily dose 1
  • CrCl 21-59 mL/min: Reduce to 260 mg daily (13 mL of 100 mg/5 mL suspension OR 6.5 mL of 200 mg/5 mL suspension) 1
  • CrCl ≤20 mL/min: Reduce to 172 mg daily (8.6 mL of 100 mg/5 mL suspension OR 4.4 mL of 200 mg/5 mL suspension) 1

Dialysis Patients 1, 2

  • Hemodialysis patients: Use the same dose as CrCl ≤20 mL/min (172 mg daily); supplemental dosing after dialysis is not necessary because hemodialysis removes an insignificant fraction of cefixime 1, 2
  • Peritoneal dialysis patients: Use the same dose as CrCl ≤20 mL/min (172 mg daily); peritoneal dialysis removes only 1.57% of the drug over 72 hours 2

Pharmacokinetic Rationale

The need for dose adjustment stems from cefixime's renal elimination pathway:

  • Approximately 40% of cefixime is cleared unchanged by the kidneys, with the remaining 60% undergoing hepatic metabolism 3
  • In patients with CrCl <20 mL/min, the elimination half-life increases from 3-4 hours to 12-14 hours 4, 5
  • Peak serum concentrations (Cmax) increase slightly in renal impairment, and drug accumulation occurs with repeated dosing if doses are not adjusted 4, 5
  • Renal clearance declines proportionally with decreasing creatinine clearance 4

Critical Clinical Considerations

Extend the dosing interval rather than reducing individual doses to maintain adequate peak concentrations for bacterial killing while preventing accumulation 4. This approach is consistent with beta-lactam pharmacodynamics, where time above MIC is the key efficacy parameter 6.

Urinary concentrations remain therapeutic even in severe renal impairment:

  • Cefixime concentrations in urine exceed MICs for most urinary tract pathogens for up to 24 hours post-dose, even with CrCl <20 mL/min 2
  • This makes cefixime particularly suitable for treating urinary tract infections in patients with renal dysfunction 2

Common Pitfalls to Avoid

Do not use the Cockcroft-Gault equation alone for modern drug dosing decisions in renal impairment; validated GFR estimation equations incorporating serum creatinine (and potentially cystatin C) are now preferred 7, 8. However, the FDA label for cefixime references creatinine clearance, so clinical judgment is needed when translating eGFR values to dosing decisions 1.

Do not give supplemental doses after hemodialysis or peritoneal dialysis, as dialysis removes negligible amounts of cefixime from the body 1, 2. This differs from some other antibiotics where post-dialysis supplementation is required 9, 10.

Monitor for accumulation in severe renal impairment (CrCl <20 mL/min), where the half-life triples and steady-state concentrations increase significantly 4, 5. While cefixime is generally well-tolerated, prolonged exposure could theoretically increase adverse effect risk 4.

References

Research

[Pharmacokinetic properties of cefixime].

Presse medicale (Paris, France : 1983), 1989

Research

Relationship between renal function and disposition of oral cefixime.

European journal of clinical pharmacology, 1991

Research

[Pharmacokinetics of cefixime in patients with impaired renal function].

The Japanese journal of antibiotics, 1986

Research

KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Guideline

Cephalexin Dosing for Patients on Intermittent Hemodialysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.